Imaavy

Imaavy (nipocalimab-aahu) has been approved as the first-ever treatment for warm autoimmune hemolytic anemia, a rare disorder in which the immune system destroys red blood cells. Observers in the biotech and pharmaceutical community are calling it a significant win for orphan diseases, where patients have historically had no approved therapy options.